| __timestamp | ImmunityBio, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 7751000 |
| Thursday, January 1, 2015 | 226206000 | 10251000 |
| Friday, January 1, 2016 | 94391000 | 9575000 |
| Sunday, January 1, 2017 | 53821000 | 10912000 |
| Monday, January 1, 2018 | 35463000 | 11049000 |
| Tuesday, January 1, 2019 | 46456000 | 11646000 |
| Wednesday, January 1, 2020 | 71318000 | 13265000 |
| Friday, January 1, 2021 | 135256000 | 25805000 |
| Saturday, January 1, 2022 | 102708000 | 35182000 |
| Sunday, January 1, 2023 | 129620000 | 94999000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. ImmunityBio, Inc. and Viridian Therapeutics, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, ImmunityBio's SG&A expenses fluctuated significantly, peaking in 2015 with a staggering 2.26 billion, while Viridian maintained a more consistent approach, with expenses rising steadily to 95 million by 2023.
ImmunityBio's expenses saw a dramatic increase of over 5000% from 2014 to 2015, highlighting a period of aggressive expansion or restructuring. In contrast, Viridian's expenses grew by approximately 1100% over the same period, indicating a more controlled growth strategy. This comparison underscores the importance of strategic financial management in the biotech sector, where every dollar counts towards innovation and development.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Vericel Corporation and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: ImmunityBio, Inc. vs Travere Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Ligand Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared